Genepharm Group (www.genepharm.com) is privately held and is committed to the development, manufacturing, marketing and distribution of a premium range of generic pharmaceutical products.

Genepharm's production facilities include three separate plants, producing:
 

• Conventional solid dosage forms - renovated in 2005
• Anti-cancer (cytostatic) solid dosage forms - inaugurated in Nov 2006
• Anti-cancer (cytostatic) sterile dosage forms - inaugurated in July 2007

 
With respect to our dossier development (CTD and e-CTD-format), Genepharm's dedicated scientific team aims at delivering several new dossiers each year.     
 
Our expert teams focus on full patent search, formulation and analytical development, on-site pilot scale production and stability trials ensuring industrial application.
 
Genepharm's global regulatory experience has been built via its direct involvement with regulatory agencies worldwide.

Core Sales Territory: All of Europe

Core Operation: Distribution, Sales and Marketing, Finished Dose Manufacture

Number of molecules sold: 28

Company's rating: